Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense for options granted, RSAs, PSAs, RSUs and SARs is reflected in the condensed consolidated statements of operations and comprehensive loss as follows:

	THREE MONTHS ENDED  MARCH 31,
(in thousands)	2020		2019
Cost of goods sold	$	497	$	—
Selling, general and administrative	6,908		9,121
Pre-approval commercial manufacturing	294		849
Research and development	2,830		2,650
Total	$	10,529	$	12,620

Schedule of Stock Options Activity

The following table summarizes the stock option activity under the Plans:

	NUMBER OF SHARES	WEIGHTED AVERAGE EXERCISE PRICE		WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (YEARS)	AGGREGATE INTRINSIC VALUE (000’s)
Options outstanding at December 31, 2019	8,425,551	$	29.06
Granted	412,417	20.94
Exercised	(11,684)	14.06
Canceled	(125,121)	41.16
Options outstanding at March 31, 2020	8,701,163	$	28.52	6.6	$	15,408
Options exercisable at March 31, 2020	5,750,958	$	25.00	5.4	$	15,408

Restricted Stock and Restricted Stock Units Activity

The following table summarizes the RSAs, including PSAs, activity under the Plans:

	NUMBER OF SHARES	WEIGHTED AVERAGE FAIR VALUE PER SHARE
Non-vested RSAs at December 31, 2019	754,415	$	43.07
Granted	82,492	21.13
Vested	(184,436)	44.27
Canceled	(18,606)	43.36
Non-vested RSAs at March 31, 2020	633,865	$	39.86

Share-based Payment Arrangement, Stock Appreciation Right, Activity

The following table summarizes the SARs activity under the Plans:

	NUMBER OF SHARES	WEIGHTED AVERAGE EXERCISE PRICE		WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (YEARS)	AGGREGATE INTRINSIC VALUE (000’s)
SARs outstanding at December 31, 2019	163,016	$	41.70
Granted	12,000	18.51
Canceled	(15,619)	41.70
SARs outstanding at March 31, 2020	159,397	$	18.51	3.8	$	1
SARs exercisable at March 31, 2020	32,610	$	52.03	3.2	$	—